MGMT Mouse Monoclonal Antibody
- Known as:
- MGMT Mouse Monoclonal Antibody
- Catalog number:
- BIN-004255-M01
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- MGMT Mouse Monoclonal Antibody
Related genes to: MGMT Mouse Monoclonal Antibody
- Gene:
- MGMT NIH gene
- Name:
- O-6-methylguanine-DNA methyltransferase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 10q26.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-16
- Date modifiied:
- 2016-10-05
Related products to: MGMT Mouse Monoclonal Antibody
Related articles to: MGMT Mouse Monoclonal Antibody
- -Nitrosodimethylamine (NDMA), a probable human carcinogen, induces toxic and mutagenic DNA -methylguanine ( MeG) adducts that are repaired by -methylguanine-DNA methyltransferase (MGMT). To elucidate how early-life environmental mutagenic exposures promote latent liver tumorigenesis, we performed longitudinal studies in wild-type and MGMT-deficient ( ) mice. Neonatal mice received NDMA intraperitoneally on postnatal days 8 and 15 and were followed for up to 10 months post-exposure. Phenomics, transcriptomics, phosphoproteomics, spatial transcriptomics, and histopathology revealed that NDMA exposure in mice produced a nine-fold increase in liver tumors, including hepatocellular carcinomas and adenomas. Early molecular profiling revealed elevated MeG adducts, sustained γH2AX activation, and increased micronucleus formation in livers. Transcriptomics showed persistent interferon response and immune cell infiltration, particularly in mice, up to 10 months post-exposure. Clonal expansion, quantified by RaDR-GFP expression, was significantly higher in NDMA-exposed mice. Spatial transcriptomics of clonally expanded cells demonstrated activation of oncogenic and inflammatory pathways. These findings demonstrate that acute early-life NDMA exposure drives persistent DNA damage signaling, chronic interferon activation, and clonal expansion that together promote MGMT-dependent hepatocarcinogenesis. Collectively, these processes link early environmental mutagen exposure to long-term premalignant evolution and tumor emergence, and define mechanistic biomarkers and potential interception targets for NDMA-induced liver cancer. - Source: PubMed
Publication date: 2026/06/23
Pribyl Lee JKay Jennifer ECorrigan Joshua JVolk Lindsay BNorales MonétOwiti Norah AKowal Evan AKohale Ishwar NNazari Ilana SSwanson Matilda RMoise Aimee CMa DuanduanLevine Stuart SMichelsen Emily MCroy Robert GRagan TimothyTorous Dorothea KAvlasevich Svetlana LDertinger Stephen DCarrasco Sebastian ESamson Leona DEssigmann John MWhite Forest MEngelward Bevin P - Patients with unmethylated O-methylguanine-DNA methyltransferase (MGMT) glioblastoma derive minimal benefit from the standard temozolomide chemoradiotherapy, leaving an urgent need for more effective therapies. The objective of this phase 2 study was to evaluate the efficacy of anlotinib plus radiotherapy in this disease. - Source: PubMed
Wu BianZhang ZhanjieMa HuiHuang JingLiu XixiShi LiangliangDong XiaochuanLei DeqiangWang XuanZhang FangchengZhao HongyangLin HongFu RongZou ZhenweiQin YouWang HaijunHu XuebinYao DongxiaoYang LinYang JinsongHong XiaohuaWang JingWen LuZhang CanLiang ZhiwenYang ZhiyongNie XinLiu GangHu FeiPeng GangJiang XiaobingYang Kunyu - Glioblastoma (GBM) incidence increases with age, and its etiologies may differ between young and elderly patients. This study aimed to investigate genetic differences between young and elderly GBM patients using next-generation sequencing (NGS) data. - Source: PubMed
Publication date: 2026/06/23
Lee Chul OuPark Sun YongYun YejinChoi Ju YoungPark Jae-SungJeun Sin-SooKim Yeo Song - In most cases, routine neuropathological analysis can clearly distinguish between methylated and unmethylated MGMT promoters in glioblastoma (GBM). However, some GBMs display weak MGMT promoter methylation. This study aimed to evaluate its impact on disease progression and survival compared with fully methylated and unmethylated cases. - Source: PubMed
Publication date: 2026/06/23
Hong BujungChaib HindMoros GonzaloTsoy YuriyZiegler SoniaHeissler Hans EMawrin ChristianShiban Ehab - Differentiating true progression (TP) from pseudoprogression (PsP) after chemoradiotherapy in gliomas remains challenging because conventional MRI findings overlap. - Source: PubMed
Publication date: 2026/06/22
Yang LinshaLiu DefengZhang DuoDu JuanShi QingleiZheng Tao